immunotherapy based biotechs into 2012, page-3

A Roadmap For Immunotherapy Success In Oncology

6 comments | February 21, 2012 |
includes:
AMGN, BMY, CELG, DNDN, GALE, GSK, IMUC.OB, MRK, NVS, ONTY



.....According to Henry Gosebruch, managing director of health-care mergers and acquisitions at J.P. Morgan, analysts at the firm expect the following:

"The large biotechs (will look) to be active acquirers in 2012.
Investors have rewarded strategic acquisitions that enhance long-term growth and companies that continue their history of developing innovative therapies, as opposed to turning into dividend-paying, share-repurchase type low-growth stocks."

The above sentiment is further supported by a report from Bloomberg, which showcased how biotech companies have historically been less active than their pharmaceutical industry counterparts regarding M&A activity.

For example, over the past 4 years, Bristol-Myers Squibb (BMY) has completed an impressive 17 acquisitions, while biotech industry heavyweight, Celgene (CELG), has completed a mere 3 acquisitions.....


http://seekingalpha.com/article/379931-a-roadmap-for-immunotherapy-success-in-oncology?source=yahoo